CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Reaffirmed by Mizuho

Share on StockTwits

Mizuho reaffirmed their buy rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a report released on Monday, AnalystRatings.com reports. Mizuho currently has a $16.00 price target on the biotechnology company’s stock.

Several other analysts have also weighed in on the company. BidaskClub lowered CytomX Therapeutics from a buy rating to a hold rating in a report on Wednesday, July 24th. Zacks Investment Research raised CytomX Therapeutics from a hold rating to a strong-buy rating and set a $14.00 price objective on the stock in a report on Wednesday, July 17th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $23.00 price target (up previously from $21.00) on shares of CytomX Therapeutics in a research note on Monday, June 3rd. Nomura reaffirmed a buy rating and issued a $22.00 price target on shares of CytomX Therapeutics in a research note on Sunday, August 11th. Finally, Cowen reaffirmed a buy rating on shares of CytomX Therapeutics in a research note on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. CytomX Therapeutics currently has an average rating of Buy and an average target price of $20.22.

Shares of NASDAQ:CTMX opened at $9.07 on Monday. CytomX Therapeutics has a 1-year low of $8.78 and a 1-year high of $24.34. The business’s 50 day moving average is $10.86 and its 200-day moving average is $11.68. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.66 and a quick ratio of 4.66.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.09). CytomX Therapeutics had a negative return on equity of 77.05% and a negative net margin of 158.05%. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $15.11 million. As a group, analysts anticipate that CytomX Therapeutics will post -2.07 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in CTMX. Nuveen Asset Management LLC acquired a new stake in CytomX Therapeutics in the 2nd quarter valued at $8,352,000. Victory Capital Management Inc. boosted its stake in CytomX Therapeutics by 79.9% in the 1st quarter. Victory Capital Management Inc. now owns 1,655,530 shares of the biotechnology company’s stock valued at $17,797,000 after buying an additional 735,320 shares in the last quarter. First Manhattan Co. acquired a new stake in CytomX Therapeutics in the 1st quarter valued at $3,461,000. Vanguard Group Inc. boosted its stake in CytomX Therapeutics by 10.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,671,374 shares of the biotechnology company’s stock valued at $29,973,000 after buying an additional 259,355 shares in the last quarter. Finally, Spark Investment Management LLC boosted its stake in CytomX Therapeutics by 105.6% in the 1st quarter. Spark Investment Management LLC now owns 432,981 shares of the biotechnology company’s stock valued at $4,654,000 after buying an additional 222,381 shares in the last quarter. 81.62% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: Calculate Your Return on Investment (ROI)

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
SBA Communications Co.  Shares Sold by Meeder Asset Management Inc.
SBA Communications Co. Shares Sold by Meeder Asset Management Inc.
Cactus Inc  Position Increased by Meeder Asset Management Inc.
Cactus Inc Position Increased by Meeder Asset Management Inc.
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA


© 2006-2019 Ticker Report